Of the CAR T-cell therapies for diffuse large B-cell lymphoma (DLBCL), Tisagenlecleucel reported a best-ever remission rate of 52% (complete response [CR] rate of 40%) (2), and axicabtagene ciloleucel reported a best-ever remission rate of 83% (CR rate of 58%) in patients (4).The current CAR NK cells clinical trials have predominantly focused on CD19+ targeting B-cell lymphomas. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.